RAPT Therapeutics Inc (RAPT) - Cash Flow Conversion Efficiency
Based on the latest financial reports, RAPT Therapeutics Inc (RAPT) has a cash flow conversion efficiency ratio of -0.082x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-12.46 Million) by net assets ($151.98 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see RAPT Therapeutics Inc market cap and net worth for the company's overall valuation and market capitalisation.
RAPT Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2017–2024)
This chart illustrates how RAPT Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
RAPT Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of RAPT Therapeutics Inc ranked by their cash flow conversion efficiency. See RAPT debt coverage from operations to evaluate how effectively operating cash flow covers total debt obligations.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
BGF Retail Co Ltd
KO:282330
|
0.188x |
|
Shenzhen Jame Technology Corp Ltd
SHE:300868
|
0.013x |
|
Unisem M Bhd
KLSE:5005
|
0.042x |
|
Photronics Inc
NASDAQ:PLAB
|
0.028x |
|
Vijaya Diagnostic Centre Limited
NSE:VIJAYA
|
0.145x |
|
Punjab & Sind Bank
NSE:PSB
|
-0.574x |
|
Sila Realty Trust, Inc.
NYSE:SILA
|
0.022x |
|
Kfin Technologies Limited
NSE:KFINTECH
|
0.108x |
Annual Cash Flow Conversion Efficiency for RAPT Therapeutics Inc (2017–2024)
The table below shows the annual cash flow conversion efficiency of RAPT Therapeutics Inc from 2017 to 2024. View RAPT live share price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $189.90 Million | $-83.30 Million | -0.439x | +33.54% |
| 2023-12-31 | $147.03 Million | $-97.05 Million | -0.660x | -128.65% |
| 2022-12-31 | $245.17 Million | $-70.77 Million | -0.289x | +11.84% |
| 2021-12-31 | $186.38 Million | $-61.03 Million | -0.327x | +15.76% |
| 2020-12-31 | $104.18 Million | $-40.49 Million | -0.389x | +19.89% |
| 2019-12-31 | $73.12 Million | $-35.47 Million | -0.485x | +5.78% |
| 2018-12-31 | $64.00 Million | $-32.95 Million | -0.515x | -218.47% |
| 2017-12-31 | $-62.41 Million | $-27.12 Million | 0.435x | -- |
About RAPT Therapeutics Inc
RAPT Therapeutics, Inc. operates as a clinical-stage immunology-based biopharmaceutical company that focuses on the discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) an… Read more